Table 2.
Biochemical and metabolic outcomes using imputation and mixed effects models – HAPIFED (n = 50) and CBT- E (n = 48)
| Group | Baseline | End of Treatment | Group | Time | Group x time | |||
|---|---|---|---|---|---|---|---|---|
| Mean ± SE | Cohen’s d (95% CI) |
Mean ± SE | Cohen’s d (95% CI) |
Chi sq, df (p value) |
Chi sq, df (p value) |
Chi sq, df (p value) |
||
| Serum glucose, mg/dL | HAPIFED | 93.51 ± 1.45 |
0.10 (−0.30 to 0.49) |
92.50 ± 1.64 |
0.15 (−0.25 to 0.55) |
0.22, 1 (0.636) |
0.02, 1 (0.896) |
0.14, 1 (0.713) |
| CBT-E | 94.49 ± 1.48 | 94.28 ± 1.74 | ||||||
| Serum insulin, ulU/mL | HAPIFED | 13.57 ± 1.17 |
−0.11 (−0.51 to 0.29) |
12.66 ± 1.29 |
−0.05 (−0.45 to 0.34) |
0.30, 1 (0.581) |
0.19, 1 (0.662) |
0.09, 1 (0.769) |
| CBT-E | 12.64 ± 1.20 | 12.19 ± 1.32 | ||||||
| Serum triglycerides, mg/dL | HAPIFED | 147.66 ± 17.78 |
−0.19 (−0.58 to 0.21) |
145.39 ± 20.08 |
−0.18 (−0.58 to 0.22) |
0.87, 1 (0.352) |
0.11, 1 (0.735) |
0.03, 1 (0.860) |
| CBT-E | 123.98 ± 18.17 | 119.03 ± 21.44 | ||||||
| Serum HDL cholesterol, mg/dL | HAPIFED | 54.55 ± 1.52A |
−0.07 (−0.46 to 0.33) |
51.88 ± 1.85B |
−0.13 (−0.52 to 0.27) |
0.11, 1 (0.744) |
4.14, 1 (0.042) |
0.11, 1 (0.743) |
| CBT-E | 53.84 ± 1.55A | 50.29 ± 1.72B | ||||||
| Serum LDL cholesterol, mg/dL | HAPIFED | 117.50 ± 4.20 |
−0.12 (−0.52 to 0.27) |
109.75 ± 5.27 |
0.01 (−0.38 to 0.41) |
0.38, 1 (0.540) |
0.54, 1 (0.463) |
0.30, 1 (0.585) |
| CBT-E | 113.84 ± 4.24 | 110.27 ± 4.92 | ||||||
Normal reference value for adults (fasted state): serum glucose 60–100 mg/dL; serum basal insulin 1.9–23.0 ulU/mL; serum triglycerides <150 mg/dL; serum HDL cholesterol >40 mg/dL; serum LDL cholesterol 100–129 mg/dL